samedan logo
 
 
spacer
home > ict > autumn 2017 > cut off
PUBLICATIONS
International Clinical Trials

Cut off

A year ago in France, hardly anybody had heard of Emanuel
Macron, who has easily defeated the National Front’s Marine
Le Pen in the recent presidential election, and, at the time
of writing, looks to have founded a party that will win an
overwhelming majority in the French Parliament. Two months
ago, the UK’s Prime Minister, Theresa May, looked to be on
course for an equally overwhelming majority in the UK general
election, but is now hanging onto her position by the skin of
her teeth. These two rather contrasting outcomes have thrown
the UK’s Brexit strategy into sharp focus.

One of the major issues in the UK election was healthcare
and the concept of ‘our’ NHS. The UK spends, per capita,
significantly less on healthcare than many EU member states.
As a proportion of GDP, it will fall to 6.6%, compared to 7.3%
in 2014/15, whereas the EU average is 1.7% higher at 9.0%.
The government’s expenditure on R&D in the sector equally
falls below the average for the group of eight countries and is
at the bottom of the list.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

spacer
Dr Graham Hughes
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

York Health Economics Consortium offers a new health utilities training course

Cost-utility analysis is a requirement for NICE health technology appraisals and is being increasingly used in other contexts and countries. Health utilities, a crucial component of cost-utility analysis, capture the relative change in health-related quality of life resulting from a treatment. As such, health utility can be a key driver of the cost-effectiveness ratio. Obtaining health utility values that are suitable for your economic evaluation, however, may not always be straight forward.
More info >>

White Papers

Orthogonal Approaches for the Analysis of Protein Sequence

Ludger Ltd

One of the most important classes of biopharmaceuticals is monoclonal antibodies. They are expressed from living cells, and are consequently subject to complex biochemical pathways. Not all of these routes are fully understood, and many are sensitive to the subtlest of environmental changes. Changes such as these can affect the final biopharmaceutical sequence, structure and post-translational modifications, not to mention any changes that may occur during further purification. This often means that the final product from one batch may be different from the last in another batch. Each batch is a complicated mix of similar molecules, and analysis of the degree of batch-to-batch variation is therefore very important to the establishment of the drug's safety for medicinal use and patient administration.
More info >>

 
Industry Events

INTERPHEX 2018

17-18 April 2018, Javits Center, New York, USA

At INTERPHEX, find all of the State-of-the-Art Solutions you need to Cost Effectively Develop and Manufacture Product. INTERPHEX is a premier pharmaceutical, biotechnology, and medical device development and manufacturing event and sponsored by Parenteral Drug Association (PDA).
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement